Enterome, Nestle Health Science partner to develop new immunotherapies

By Pranali Mehta  | Date: 2022-07-19

Enterome, Nestle Health Science partner to develop new immunotherapies

Enterome, a leading clinical stage biopharmaceutical firm has declared a strategic Research and Development license alliance and partnership with Nestle Health Science focusing on inflammatory bowel diseases and food allergies.

Crucial to mention that Enterome is forming its first-ever immunomodulatory drug on the basis of extremely productive bacterial Mimicry drug discovery platform.

As per reports, the partnership aims to successfully commercialize and develop EndoMimics, Enterome’s main pipeline contender EB1010. It is a potential local inducer of IL-10 made to offer improvised therapeutic results for the patients with inflammatory bowel diseases and food allergies.

Moreover, EB1010, which is all set to enter clinical trials in 2023, has been utilizing novel bacteria Mimicry drug discovery platform of Enterome and the same will be used to develop and identify latest EndoMimics as potential novel therapies for inflammation related to food allergies.

Furthermore, the agreement also aims to create and identify a pipeline of novel AllerMimics by using Enterome’s Mimicry stage with the starting emphasis on peanut allergens as the ground for a novel range of immunotherapies that will bring down the allergic reactions.

According to the terms of the alliance, Enterome will receive USD 40.8 million upfront in equity and in cash from Nestle Health Science and is also capable to get sales and clinical milestone payments for every authorized therapeutic contender along with royalties on net sales.  

Not to mention, Enterome will be responsible for increase in bear related costs and leading drug discoveries to the investigational new drug application.

For the record, Enterome’s Mimicry drug discovery platform is centric to its exceptional ability to decode the interaction between the immune system and the gut microbiome.

The Mimicry platform uses top-class biocomputational bioassays and tools to identify novel therapeutics for a large range of indications from a patented database of 20+ million complete-length gut microbiome proteins and peptides.

Source Credits: - https://www.prnewswire.com/news-releases/enterome-signs-major-strategic-rd-collaboration-with-nestle-health-science-to-develop-and-commercialize-new-allermimics-and-endomimics-immunotherapies-for-food-allergies-and-inflammatory-bowel-disease-301587952.html

About Author

Pranali Mehta     aeresearch.net

Pranali Mehta

A chemical engineer by qualification, Pranali Mehta has dutifully walked down the slated path and worked in the chemicals industry for a year. Her passion for writing however, pushed her into experimenting with the same as a career. With over three years of experience...

Read More